This company is a specialty biopharmaceutical company that has established a drug development platform to actualize an orally administered, low-dose version of the drug interferon, which is a well characterized immune system modulator. Interferon serves as one of the most fundamental immune system signaling agents in the body, with the extensive capabilities of initiating, amplifying and ending an immune system response. Accordingly, high doses of injected interferon has been shown to be a powerful therapeutic tool, used for over twenty years to treat wide ranging conditions including cancer, hepatitis, genital warts and the autoimmune disease multiple sclerosis. However, the high dose required via injection of interferon causes severe side effects including muscle aches, fever, and chills amongst other more serious adverse reactions, and can lead to the discontinuation of the drug by certain patients. The company’s technology addresses this complication by utilizing the mucosa lining of the oral and throat cavity to deliver low-doses of interferon that achieve the same therapeutic benefits as high doses, but without the severe side effects. The company’s interferon drug is currently being used in three separate Phase II clinical trials to treat influenza, chronic cough, and hepatitis c.
[button link=”http://www.onemedplace.com/database/list/cid/128″ color=”lightblue”]Continue for more info[/button]
Categories: cancer, COMPANIES, MEMBER NEWS, Member Spotlight
